Singapore researchers advance phage therapy in fight against antimicrobial resistance

SINGAPORE – Scientists from A*STAR Infectious Diseases Labs (A*STAR IDL), Nanyang Technological University, Singapore’s Lee Kong Chian School of Medicine (LKCMedicine), the National University of Singapore (NUS), and international collaborators have uncovered how Mycobacterium abscessus – a bacterium that causes serious lung infections – can evade bacteriophage (phage) therapy, and demonstrated a combination strategy to overcome this resistance, offering a pathway towards more effective and durable treatments. The study was published in the Proceedings of the National Academy of Sciences.

Antimicrobial resistance (AMR) is an escalating health challenge that is expected to place growing strain on healthcare systems worldwide. As AMR continues to erode the effectiveness of existing antibiotics – with one in six bacterial infections worldwide now resistant to antibiotics – scientists are accelerating efforts to develop new countermeasures such as phage therapy, which uses viruses to target bacteria. These efforts are important for strengthening global health and infectious disease preparedness.

Understanding How Bacteria Adapt to Survive Treatment

M. abscessus infections are challenging to treat due to their intrinsic resistance to many antibiotics and are increasingly recognised as a significant public health threat.

The researchers found that “smooth” strains of M. abscessus, which are more commonly observed in Asia, respond to phage therapy by switching to a “rough” form, both in the laboratory and pre-clinical models. This transition is linked to mutations in genes responsible for producing glycopeptidolipids, which shape the bacteria’s outer surface.

In other cases, the bacteria resisted phage attack without changing form, instead developing mutations in different surface‑related genes, revealing multiple pathways to resistance.

The team uncovered this resistance mechanism while generating phage‑resistant bacterial mutants to investigate phage‑bacteria interactions.

“These findings reveal an important challenge in developing phage‑based therapies. Although phages can effectively eliminate bacteria, they may also inadvertently make infections more difficult to treat, as seen in the ‘rough’ form,” explained Professor Pablo Bifani, senior author and scientist at LKCMedicine.

Designing More Effective Phage Treatments to Treat AMR Infections

To address this, the team developed a combination therapy targeting both the original “smooth” bacteria and the emerging “rough” variants. This two‑pronged approach proved more effective than a single-phage treatment, pointing toward more robust and longer‑lasting phage therapies for patients.

“What started as a straightforward goal: finding phages that can target M. abscessus smooth strains, led us to the discovery of a clinically relevant resistance mechanism,” said Dr Liew Jun Hao, first author and scientist at A*STAR IDL.

“Phage therapy holds great promise as an alternative treatment for AMR infections, and our findings show that how these treatments are designed is critical. By identifying these ‘escape states’, our study underscores the need for the field to systematically account for bacterial adaptation, so that strategies to counter phage resistance can be built into therapies from the outset, as the threat of AMR continues to grow.”

Associate Professor Albert Yick Hou Lim, Senior Consultant in Respiratory and Critical Care Medicine, Tan Tock Seng Hospital, who was not part of the study team, said: “In clinical settings, infections caused by M. abscessus are challenging to treat due to limited effective therapeutic options. These findings highlight the importance of anticipating how bacteria may respond to treatment. Strategies that account for such adaptive responses, including combination phage therapies, may enhance treatment durability, improve patient outcomes, and better inform clinical management of these complex infections.”

Advancing Novel Therapeutics and Diagnostics Against AMR

By revealing how phage resistance happens, and how it can be mitigated, this study strengthens the ongoing efforts to develop novel therapeutics against AMR.

The findings may also inform future diagnostic and monitoring approaches, such as tracking bacterial form changes and resistance-associated mutations. This could help clinicians tailor treatments and adjust therapeutic strategies more responsively.

Beyond immediate clinical applications, understanding how bacteria evolve under therapeutic pressure is important for infectious disease preparedness. Such insights can inform the design of new therapies that remain effective even as pathogens adapt.

The study contributes to Singapore’s efforts to strengthen capabilities in infectious diseases research and develop solutions to address emerging global health challenges.

– END –

Enclosed:

ANNEX A – Notes to Editor on Research Findings

For media queries and clarifications, please contact:

Aileen Tan

Manager, Corporate Communications

Agency for Science, Technology and Research

Tel: +65 9186 6450

Email: aileen_tan@a-star.edu.sg

______________________________________________________________________

About the Agency for Science, Technology and Research (A*STAR)

The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry. A*STAR’s R&D activities span biomedical sciences to physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit www.a-star.edu.sg.

Follow us on

Facebook | LinkedIn | Instagram | YouTube | TikTok

About A*STAR Infectious Diseases Labs (A*STAR IDL)

A*STAR Infectious Diseases Labs (A*STAR IDL) was established in April 2021 with a mission to be a leading research institute of infectious diseases in antimicrobial resistance, respiratory and vector-borne diseases. A*STAR IDL brings together infectious diseases expertise from across multiple disciplines to drive cutting edge translational infectious diseases research to contribute to Singapore’s national preparedness and defence against the threat of emerging infections. Building upon a robust foundation of our strong biomedical research capabilities and complemented by our globally connected scientific network, A*STAR IDL aims to focus on innovative technologies in infectious disease detection, intervention and prevention with a pathway to impact on health and economic outcomes. https://www.a-star.edu.sg/idlabs

Follow us on

Facebook | LinkedIn | Instagram